Nogo-A receptor internalization by cyclic adenosine monophosphate in overcoming axonal growth inhibitors after stroke
Rayudu Gopalakrishna1
Charlotte Lin1
Mark S.Kindy2
William J.Mack3
1.Department of Integrative Anatomical Sciences,Keck School of Medicine,University of Southern California,Los Angeles,CA,USA2.Department of Pharmaceutical Sciences,College of Pharmacy,University of South Florida,Tampa,FL,USA3.Department of Neurological Surgery,Keck School of Medicine,University of Southern California,Los Angeles,CA,USA
摘要：Currently, there are no clinically proven drugs for recovery from stroke and other neuronal injuries such as traumatic brain injury and spinal cord injury. Recovery therapy requires axonal regeneration, which is inhibited by diverse axonal growth inhibitors, such as Nogo-A, myelin-associated glycoprotein (MAG), oligodendrocyte myelin glycoprotein (OMgp), and chondroitin sulfate proteoglycans (CSPGs) (Chaudhry and Filbin, 2007; Carmichael, 2010; Schwab and Strittmatter, 2014). A cell-surface receptor for Nogo-A, NgR1, mediates the inhibitory action of not only Nogo-A but also other axonal inhibitors (MAG, OMgp, and CSPGs) as well.
机标关键词：
论文发表日期：2022-01-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：2( 91-92 )